BCDA stock forecast, quote, news & analysis
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs... Show more
Why BioCardia (BCDA) Stock Is Down -22% in the Last 30 Days
Key Takeaways
- BCDA shares declined approximately 22% over the last 30 days, falling from a closing price of $1.09 on October 7 to $0.85 on November 6.
- The drop occurred despite a string of regulatory milestones, including FDA acceptance of the Helix catheter pre-submission package and completion of Japan PMDA consultations.
- Investor concerns center on BioCardia's thin cash position, ongoing share dilution, and the Nasdaq $1.00 minimum bid price requirement.
- Over the trailing quarter, the stock is down roughly 10% after peaking near $1.25 in mid-September and reversing lower.
- For deeper analysis, review BioCardia's Price Targets, Earnings, and Forecast pages.
- Explore curated, top-performing strategies in Trending AI Robots.
BioCardia (BCDA) Company Overview and Market Position
BioCardia, Inc. is a clinical-stage regenerative medicine company headquartered in Sunnyvale, California, focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead program, CardiAMP, is an autologous mononuclear cell therapy in late-stage development for ischemic heart failure with reduced ejection fraction (HFrEF) and for refractory angina. The company is also advancing CardiALLO, an allogeneic mesenchymal stem cell therapy. These platforms are enabled by proprietary devices, including the Helix biotherapeutic delivery catheter, the Morph DNA vascular navigation portfolio, and the Heart3D fusion imaging platform under development. BioCardia is pre-revenue, so investors follow the stock primarily for clinical data, regulatory decisions, and financing developments rather than operating earnings.
BioCardia (BCDA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BCDA fell from a closing price of $1.09 on October 7 to $0.85 on November 6, a decline of roughly 22%. The move was not a single-event crash but a steady slide, with the stock breaking below the $1.00 level in mid-October and continuing lower into early November.
The trailing quarter tells a more volatile story. From about $0.95 in early August, shares rallied to a peak near $1.25 in mid-September before reversing. Measured from early August to the latest close, the stock is down approximately 10% over the quarter, meaning the entire gain from the late-summer rally has been given back.
What Drove BCDA Stock Price in the Last 30 Days
The 30-day decline unfolded despite a steady stream of company announcements. On October 1, BioCardia filed a revised De Novo pre-submission for FDA marketing clearance of its Helix catheter. It presented the CardiAMP HF II trial design at the Heart Failure Society of America meeting on October 7, and on October 19 it announced that the FDA had accepted the Helix pre-submission package. These steps, however, were procedural milestones rather than approvals, and the market treated them as such.
The more powerful forces were financial. BioCardia ended its second quarter with roughly $4 million in cash against a burn rate of about $1.7 million per quarter, and it has funded operations through at-the-market share sales that have grown its share count. The stock's move below $1.00 in October also renewed attention on the Nasdaq minimum bid price requirement, adding to selling pressure in a thin, micro-cap security. These dilution and balance-sheet concerns outweighed the regulatory progress during the period.
What Drove BCDA Stock Performance Over the Last Quarter
The quarterly trend reflects a familiar pattern for early-stage biotechs: a catalyst-driven rally followed by a retreat as fundamental financing concerns reassert themselves. Shares climbed through August after BioCardia reported second-quarter results and announced FDA confirmation of Helix meeting minutes, then extended higher into mid-September around the H.C. Wainwright investment conference and a corporate update on Helix and Japan PMDA timing. The rally stalled near $1.25, and the stock subsequently unwound as investors refocused on cash runway, dilution, and listing compliance. The net result is a roughly 10% decline over the quarter despite a meaningful run of clinical and regulatory news.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a platform that operates hundreds of bots across thousands of tickers. Rather than listing every strategy, the section surfaces the top-performing and most relevant bots, each of which varies in trading strategy, timeframe, and performance metrics. This makes it a useful starting point for traders and investors who want to monitor quantitative, rules-based approaches alongside their own research. Explore the page to see which automated strategies are currently gaining attention.
BCDA Stock Forecast Drivers: What Investors Should Watch Next
Several near-term factors are likely to shape BCDA. The company has indicated it is working toward a Shonin pre-market regulatory submission to Japan's PMDA in the fourth quarter, while the FDA's substantive review and meeting on the Helix De Novo pre-submission are expected this quarter. Enrollment progress in the confirmatory CardiAMP HF II trial and updates on the company's cash position and financing plans will also be closely watched, as will the next quarterly earnings report. Maintaining compliance with the Nasdaq minimum bid price requirement remains an important technical consideration. None of these catalysts guarantee a particular price outcome, and the balance between regulatory progress and balance-sheet pressure will likely continue to drive sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BCDA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BCDA turned positive on November 10, 2026. Looking at past instances where BCDA's MACD turned positive, the stock continued to rise in 41 of 47 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BCDA's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 64 cases where BCDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on BCDA as a result. In 86 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +9.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCDA advanced for three days, in 183 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
BCDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
BCDA moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BCDA crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for BCDA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. BCDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.766) is normal, around the industry mean (3.498). P/E Ratio (-1.441) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage regenerative medicine company, which develops novel therapeutics for cardiovascular diseases
Industry Biotechnology